NGS Streamlines Biomarker Testing in Solid Tumors
Chen, PharmD, MS, BCOP, CPP, discusses the role of next-generation sequencing in improving biomarker testing and treatment planning for solid tumors.
- Experts including Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, share insights on this topic.
- Other contributors include Mark Agulnik, MD, Mrinal M. Guckerman, and Daniel Lefler, MD.
- Additional experts such as Naval G. Daver, MD, and Jessica Altman, MD, also provide their perspectives.
Next-generation sequencing improves biomarker testing and treatment planning in solid tumors.
Authors include Estelamari Rodriguez, MD, MPH, Millie Das, MD, and Ruham Nasany, MD, among others.
Author's Summary
Next-generation sequencing enhances biomarker testing for solid tumors.
More News
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Second Phase of FIFA 2026 World Cup Tickets Launches
- How Gaming Glasses Are Becoming Essential for Gamers? | NorthPennNow
- First Duel Night Abyss Figure Is Based on Psyche
- Newsom considering 2028 run, calls Trump an ‘invasive species’
- Bitcoin Price Might Never Fall Below $100,000 Again
- Why Frustrated Boomers Are the Senior Living Industry’s Biggest Potential Disruptors
- TFSA Million Dollar Blueprint: The Only Canadian Stock You'll Need
- SJHN Daily: Celebrini Named NHL First Star of the Week
- Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight